echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The third round of state-owned drug companies into the main force: Qilu, Yangzijiang, Zhongsheng Pharmaceuticals.

    The third round of state-owned drug companies into the main force: Qilu, Yangzijiang, Zhongsheng Pharmaceuticals.

    • Last Update: 2020-09-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Review the third batch of national mining, involving a total of 56 varieties, 82 product regulations, the amount of 22.6 billion yuan, a total of 194 enterprises involved, affecting more than 50 well-known domestic and foreign listed pharmaceutical companies.
    , 55 varieties won the bid, Ramif Ding due to limited reporting, insufficient incentive for enterprises to reduce prices, into the only falling varieties.
    , the third batch of state-owned mining produced a total of 125 selected enterprises, 191 selected drug product regulations, an average price reduction of 53%, the highest decline of more than 95%.
    On the current results of the election, located in the pharmaceutical industry's first echelon of domestic pharmaceutical companies are still the main force in this collection, continuing the previous rounds of national drug collection of the main position, and the original drug research enterprises exit strategy is very obvious.
    Among the Chinese pharmaceutical companies, Qilu Pharmaceuticals and Shi Pharmaceutical Group have successfully won the 8 varieties of the proposed qualification, Yangzijiang Pharmaceutical Group, Shanghai Pharmaceutical Group, China Biopharmaceuticals won 7 varieties, Hengrui Pharmaceuticals, Howson Pharmaceuticals, also won 4 and 5 varieties respectively.
    only three of the original varieties were selected, namely - the methylcobalamin tablets of the ingredients, the left ethyl iracetam injections of Ukip, and Pfizer's Lenazine tablets.
    is worth noting that the third batch of state-owned pharmaceutical companies involved in the offer varieties are not many.
    According to combing, a total of 194 pharmaceutical companies submitted 354 varieties of quotations, of which 43 varieties were submitted by foreign pharmaceutical companies - of which Mercado and Pfizer involved five varieties, Lilly, Novarma, AstraZenetel and Ukip involved three varieties, and Astellas and Squirbor involved two varieties.
    domestic head pharmaceutical enterprises, into the public hospital drug market from the final decline, the competition between domestic generic drug companies is still very fierce, many domestic pharmaceutical companies in good faith.
    analysis points out that due to the rapid progress of the evaluation of the consistency of domestic enterprises in the early stage, the number of enterprises participating in the third batch of state-owned enterprises has increased dramatically, and competition has intensified.
    specifically, there are as many as 16 pharmaceutical companies involved in the number of generic companies reached more than five.
    the number of enterprises participating in the auction was as high as 30, ranking first among the 56 varieties of participating enterprises.
    , for example, metformin oral regular release dosage form, there are as many as 28 enterprises qualified to declare.
    In terms of bidding, there have been significant price reductions of more than 90 per cent for a number of varieties - including Qilu's Apixaban, Connbe's Fernasamine, Chongqing Core Pharmaceuticals' Catopri, Stone And Qilu's Meigang, Qilu and Synth's Tofatib, which have fallen by more than 95 per cent.
    From the point of view of variety competition, Catopri oral regular release dosage form, oral regular release dosage form for Guerrero,acid sidina non-tablets and other varieties of competition is very fierce, all pharmaceutical companies reported a price reduction of more than 95%.
    , for example, the stone drug Euro intends to bid 0.165 yuan / tablet in the bidding for the oral regular release agent type, compared with the current price of 12.8622 yuan / tablet on the basis of a price reduction of nearly 99%.
    Chongqing Corey Pharmaceuticals offered 0.0142 yuan per tablet for Katopuri's oral regular release dosage form, a drop of more than 95%.
    the three most competitive varieties, metformin oral regular release agent type, metformin slow-controlled release agent type, Katopuri oral regular release agent type, the average decline of 82%, 71%, 93%, of which Chongqing Core Pharmaceuticals gave the two varieties of the highest decline - metformin oral regular release agent type decreased by 92.3%, Katopri oral normal release agent type decreased by 95.82%.
    This Qilu is to achieve 8 products Capertabin tablets,acid sidina non-tablets, apixaban tablets, o nitrogen flat mouth collapse tablets, Mengrust sodium chewing tablets,acid tofatin tablets, Viglitin tablets, relying on the kaoxi tablets are winning the bid.
    It must be said that Qilu, as the head of the domestic pharmaceutical industry, actively participate in the centralized procurement of drugs organized by the state at a fairly low price, and successfully selected on a number of varieties, for the pharmaceutical industry has a good demonstration effect.
    Although some voices in the industry have different views on this strategy, but from the national policy level, the centralized procurement of drugs organized by the state is a major reform, the purpose is to allow the people to use higher quality drugs at relatively low prices.
    It can be said that enterprises that dare to offer low prices to the courage to effectively reduce the burden of drug use of patients, and through their own price reduction and the substitution effect of the original drug, to achieve the reduction of national health insurance efficiency, improve the efficiency of the use of medical insurance funds, but also to expand the scope of medical security, improve the level of protection of ordinary people to create conditions.
    to some extent, drug safety involves the people's health, enterprises to provide patients with safe and effective drugs at low prices is the direct embodiment of enterprises from their own role, and actively assume social responsibility.
    In accordance with the confirmation rules of the supply provinces of the selected varieties in the follow-up collection, the low-cost winning Qilu Pharmaceuticals also qualified as a preferred supply province, that is to say, in terms of these seven varieties, Qilu Pharmaceuticals will win the widest market.
    noteworthy, Qilu in the West End, with a 92.7% decline in the success of the original market share of the two pharmaceutical companies Pfizer, Baiyunshan, achieved the exclusive winning bid.
    specifically, in the West China Sea, the original drug company Pfizer's offer exceeded the maximum price of 21.87 percent, basically automatically abandoned.
    baiyunshan's quotation in the decline, fuse mechanism, or absolute value of the three dimensions have not been able to comply with the relevant rules of the declared price, and finally regret to leave the scene.
    According to industry insiders to Seberland, the cost of non-films in The West is not high, although Qilu's decline of up to 90%, but considering its original market share is limited, as well as a strong willingness to enter the market, this offer is more reasonable.
    It should be noted that pharmaceutical companies in the quotation, has taken the initiative to squeeze out the water in the circulation link, the reason for achieving a significant price reduction, mainly because pharmaceutical companies for the national collection has a great understanding and participation, as well as a strong API and production cost control capacity.
    is worth noting that in the third batch of many varieties, Xidana is not only one of the attention of public opinion.
    is a first-line therapeutic drug for male erectile dysfunction (ED) and is the largest product in the ED market, with a market share of more than 70%.
    , unlike many varieties, the retail market in West Tanao is much larger than that in hospitals.
    2019, the size of the national retail market in Xidina non-china was 2.37 billion yuan, while the size of the national hospital market was only 120 million yuan, according to data from the National Hospital Network.
    there is a set of data to support this situation - as the first province to implement simultaneous pharmacy and hospital reporting, Guangdong Province pharmacy West Tana non-reporting is 1,522 times the hospital's. in 2019, Pfizer's Van Ayew has an absolute advantage in public hospitals, with a market share of 94.38 percent, with the rest split between Baiyunshan and Yabang Pharmaceuticals, and Qilu can be described as a "barefooter," according to
    M.com.
    this time, Qilu Pharmaceutical's exclusive winning will directly with a clear price advantage to win the Western Non-national public hospital 50% of the market.
    In addition, due to the strong variety of Western non-retail pharmacies, as more retail pharmacies continue to join the national drug collection, as well as retail terminals for the high sensitivity of drug prices, Qilu's Sidna non will also win the retail market share at an absolute price advantage.
    Because many of the third batch of national varieties of the original market share is mainly occupied by the original pharmaceutical companies, such as Capithamin and Anaquotol tablets, two large varieties - according to PDB sample hospital data, sales in 2019 were 1,008 million yuan, 423 million yuan, of which Roche and AstraZeneca accounted for 75.14 percent and 87.43 percent of the market share, respectively.
    In the collection auction, Roche and AstraZeneta are far higher than the highest effective declared price of the bid, the winning domestic pharmaceutical companies will directly access the public hospital market, no doubt, with the third batch of national harvest landing, the market pattern of these varieties will be rewritten.
    National drug collection, reverse forced drug enterprises transformation and upgrading With the national organization of drug centralized volume procurement of the normal, the national organization of drug collection has become to reduce medical insurance expenditure, reduce the burden of patients, squeeze drug moisture, promote the transformation and upgrading of enterprises inevitable action.
    Review the results of previous rounds of collection - in the first round of 4-7, the average price of 25 varieties proposed to be selected decreased by 52%, a maximum decrease of 96%; The decline was 59 per cent, a further 25 per cent on the basis of the 4-plus-seven, the average price reduction for 32 drugs in the second round of the national organization of drug collection was 53 per cent, the highest decline was 93 per cent, and the average decline for 55 products was estimated to be 53 per cent, based on the results of the third round of national selection.
    Under the mechanism of volume procurement, recruitment and collection, volume-for-price, volume-price linkage, domestic pharmaceutical companies exchange prices for the market, actively participate in the collection of drugs organized by the state, saving a lot of medical insurance funds, but also reduce the burden on patients.
    In the second batch of national organizations centralized procurement and use of drugs in response to a reporter's question, the pilot office, the head of the joint procurement office made it clear that the national organization of drug collection is an important project to enhance people's livelihood and well-being - centralized procurement of drugs in reducing the burden of patient costs at the same time, improve the quality of clinical drug use.
    from the field of treatment, the selected drugs mainly cover diabetes, hypertension, anti-tumor and leukemia and other common chronic diseases, malignant diseases, is expected to benefit the domestic population of more than 100 million patients.
    In addition, statistics show that the cost of 57 selected drugs collected by the first two batch of state-organized drugs decreased from 42.7 billion yuan to 8.3 billion yuan, with direct savings of 34.4 billion yuan -- of which 18 billion yuan was reduced and 16.4 billion yuan was replaced.
    must say that the $18 billion price reduction effect is due to the domestic head drug companies mainly generic groups of enterprises firmly involved in the national collection, and take the initiative to reduce drug prices.
    qilu as an example, so far, in the national drug collection, Qilu Pharmaceutical has won a total of 17 products.
    must see that in participating in the national collection and actively reduce prices on the other side is the enterprise continued to invest human and material resources, and actively layout of consistent evaluation work to obtain the qualification of the collection finalists.
    in the face of participating in the national organization of drug collection enterprises, there has been no shortage of questioning voices in the industry, such as low price quality how to ensure, no profit how to innovate and so on.
    On the first issue, the reason why the national collection can force enterprises to report such low prices, because of its price exchange, to ensure the use of compressed drugs in the circulation of water and gold sales space, since the main squeeze out of the circulation of water, naturally will not affect the quality of drugs.
    In addition, in many rounds of national harvesting, there are supporting policies to ensure quality, such as the regular inspection of the Drug Administration, in addition, Chinese drug companies are also using practical actions to improve production efficiency, reduce production costs, to ensure product quality.
    On the second issue, it has been proved that from the selection of domestic pharmaceutical enterprises' development strategy, there is no shortage of enterprises will turn to cost control of generic drug development lines, but adhere to innovation enterprises will not because of the state organization of drug collection to stop their own investment in research and development.
    with the full entry of generic drugs into the era of micro-profit, many domestic generic drug giants began to increase the layout of innovative drugs, such as Qilu, Shi medicine, Fosun, China Biopharmaceuticals, Hengrui and so on.
    The development experience of large multinational pharmaceutical companies has shown that whether through external purchase or independent research and development, the continuous introduction of innovative drugs, and the creation of competitive product pipeline is an important way for pharmaceutical companies to remain profitable and win.
    Can see that in the realization of generic drug quality and effect consistent, and through the national organization of drug collection and compression of generic drug moisture, the relevant departments are also through accelerated review and approval, health insurance negotiations and other ways, strongly support the development of innovative drugs, it should be said that the enterprises involved in innovative drugs have ushered in a good era.
    still take Qilu as an example, from the data, it has clearly moved towards innovative drugs - in 2018, Qilu research and development investment reached 1.8 billion yuan, in 2019, Qilu research and development investment of 2.06 billion yuan, research and development investment in 2020 is expected to account for more than 10% of sales revenue.
    With the investment comes the harvest season of innovative drugs, so far, Qilu has more than 50 projects accelerated, of which 5 have entered clinical trials, 2020 will have 10 declared IND, the next five years will have more than 40 declared IND.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.